Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial of BDC-1001 ± Pertuzumab in HER2-positive Metastatic Breast Cancer After Trastuzumab Deruxtecan
2023-506038-65-00Phase 2Completed
- Sponsor
- Bolt Biotherapeutics
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial in HER2-enriched breast cancer (HER2+) comparing BDC-1001 monotherapy with BDC-1001 + pertuzumab (2 arms). Primary endpoint: Objective response rate. Started Feb 2024; status: completed.
02
Drugs
bdc-1001pertuzumab
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on 2023-506038-65-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506038-65-00.